10-Q: NeuroBo Pharmaceuticals Reports Q1 2024 Results, Progresses Clinical Trials

NeuroBo Pharmaceuticals reported a net loss of $6.7 million for the first quarter of 2024, while advancing its clinical programs for MASH and obesity.

Summary

• NeuroBo Pharmaceuticals reported a net loss of $6.7 million for the first quarter of 2024, compared to a net loss of $2.6 million in the same period last year.
• The company's operating expenses increased significantly to $6.9 million, primarily due to higher research and development costs associated with ongoing clinical trials.
• Research and development expenses surged to $4.9 million, driven by the Phase 2a trial for DA-1241 and the Phase 1 trial for DA-1726.
• General and administrative expenses also saw a slight increase to $2.0 million.
• The company's cash balance stood at $16.0 million as of March 31, 2024, and they anticipate this will fund operations into the fourth quarter of 2024.
• NeuroBo is actively pursuing additional funding through equity offerings, debt financing, and potential collaborations.
• The Phase 2a trial for DA-1241 completed enrollment for Part 1 in April 2024, with full trial data expected in the second half of the year.
• The Phase 1 trial for DA-1726 dosed its first patient in April 2024, with top-line data from Part 1 expected in the third quarter of 2024 and Part 2 in the first quarter of 2025.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there is progress in clinical trials, the significant increase in net loss and the going concern warning temper the positive aspects. The company's reliance on future funding also introduces uncertainty.

Positives

• The company successfully completed enrollment for Part 1 of the Phase 2a trial for DA-1241 in April 2024.
• The Phase 1 trial for DA-1726 commenced dosing its first patient in April 2024.
• The company received SRC approval to continue the DA-1241 Phase 2a trial without modification.
• Positive pre-clinical safety data was reported for DA-1241 in combination with sitagliptin.
• The FDA cleared the Investigational New Drug (IND) application for the Phase 1 trial of DA-1726.

Negatives

• The company experienced a significant increase in net loss, from $2.6 million in Q1 2023 to $6.7 million in Q1 2024.
• Operating expenses increased substantially, primarily due to higher R&D costs.
• The company has an accumulated deficit of $115.0 million as of March 31, 2024.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company is reliant on raising additional capital to fund operations.

Risks

• The company's ability to continue as a going concern is dependent on securing additional funding.
• There is no assurance that the company will be able to obtain financing on acceptable terms.
• The company may experience significant dilution if it raises additional funds through equity offerings.
• Debt financing, if available, may involve restrictive covenants that impact the company's ability to conduct business.
• Failure to raise additional capital may lead to a slowdown or halt of ongoing and planned clinical trials.
• The company is subject to significant risks and uncertainties, including failing to secure additional funding before achieving sustainable revenues and profit from operations.

Future Outlook

The company expects to report full trial data for the DA-1241 Phase 2a trial in the second half of 2024, and top-line data from the DA-1726 Phase 1 trial in the third quarter of 2024 (Part 1) and the first quarter of 2025 (Part 2). The company believes its existing cash will fund operations into the fourth quarter of 2024 and plans to continue to fund operations through a combination of equity offerings, debt financings, or other sources.

Management Comments

• Management believes that the existing cash will be sufficient to fund operations into the fourth quarter of 2024.
• Management plans to continue to fund operations through a combination of equity offerings, debt financings, or other sources, potentially including collaborations, out-licensing and other similar arrangements.

Industry Context

The company is operating in the competitive biotechnology sector, focusing on treatments for cardiometabolic diseases, specifically MASH and obesity, which are areas of significant unmet medical need. The company's focus on novel GPR119 and GLP-1/glucagon dual agonists aligns with current trends in drug development for these conditions.

Comparison to Industry Standards

• NeuroBo's increased R&D spending is typical for a clinical-stage biotech company advancing multiple programs.
• The reported net loss is consistent with the financial profile of companies in this stage of development, which are typically pre-revenue and heavily investing in clinical trials.
• The company's cash runway into the fourth quarter of 2024 is a critical factor, as many biotech companies face similar funding challenges.
• Comparable companies in the space include those developing treatments for MASH and obesity, such as Madrigal Pharmaceuticals, Viking Therapeutics, and Eli Lilly, which are also investing heavily in clinical trials and facing similar financial pressures.
• The company's reliance on external funding is a common theme in the biotech industry, where capital raises are often necessary to support ongoing research and development.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not currently a party to any claims or legal proceedings that are likely to have a material adverse effect on its business.

Related Party Transactions

• The company has a license agreement and a shared services agreement with Dong-A ST Co. Ltd., a related party.
• The company incurred R&D expenses of $175 thousand and $326 thousand for the three months ended March 31, 2024 and 2023, respectively, under the Shared Services Agreement with Dong-A.

Stakeholder Impact

• Shareholders may experience significant dilution if the company raises additional funds through equity offerings.
• Employees may be affected by potential slowdowns or halts in clinical trials if the company is unable to raise additional capital.
• The company's ability to continue as a going concern impacts all stakeholders, including shareholders, employees, and partners.

Next Steps

• The company will continue to enroll patients in Part 2 of the Phase 2a trial for DA-1241.
• The company will continue to enroll patients in the Phase 1 trial for DA-1726.
• The company expects to report full trial data for the DA-1241 Phase 2a trial in the second half of 2024.
• The company expects to report top-line data from the DA-1726 Phase 1 trial in the third quarter of 2024 (Part 1) and the first quarter of 2025 (Part 2).
• The company will continue to seek additional funding through various means.

Key Dates

Keywords

NeuroBo Pharmaceuticals, clinical trials, MASH, obesity, DA-1241, DA-1726, GPR119 agonist, GLP-1 receptor, glucagon receptor, biotechnology, pharmaceuticals, research and development